Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lipsky

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Haematologica|June 21, 2006
Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosusPaolo A Muraro, Nikolay P Nikolov, John A Butman, et al.
Arthritis and Rheumatism|April 16, 2002
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussionDésirée van der Heijde, Lee Simon, Josef Smolen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 27, 2019
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus ErythematosusRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Frontiers in Pharmacology|January 10, 2022
Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone<sup>®</sup>Peter Lipsky, Patrick T Vallano, Jeffrey Smith, et al.
Journal of the American Academy of Dermatology|October 26, 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trialVictoria P Werth, Joan T Merrill, Richard Furie, et al.
The Journal of Rheumatology|December 2, 2021
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension StudyRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Lupus Science & Medicine|August 3, 2023
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspectiveJoy Buie, Lauren Bloch, Eric F Morand, et al.
Lancet (London, England)|September 26, 2018
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled studyRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 3, 2020
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus ErythematosusMatteo Cesaroni, Loqmane Seridi, Matthew J Loza, et al.
Arthritis Research & Therapy|August 11, 2018
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trialTanja Alexandra Stamm, Klaus Peter Machold, Daniel Aletaha, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Haematologica|June 21, 2006
Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosusPaolo A Muraro, Nikolay P Nikolov, John A Butman, et al.
Arthritis and Rheumatism|April 16, 2002
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussionDésirée van der Heijde, Lee Simon, Josef Smolen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 27, 2019
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus ErythematosusRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Frontiers in Pharmacology|January 10, 2022
Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone<sup>®</sup>Peter Lipsky, Patrick T Vallano, Jeffrey Smith, et al.
Journal of the American Academy of Dermatology|October 26, 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trialVictoria P Werth, Joan T Merrill, Richard Furie, et al.
The Journal of Rheumatology|December 2, 2021
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension StudyRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Lupus Science & Medicine|August 3, 2023
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspectiveJoy Buie, Lauren Bloch, Eric F Morand, et al.
Lancet (London, England)|September 26, 2018
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled studyRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 3, 2020
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus ErythematosusMatteo Cesaroni, Loqmane Seridi, Matthew J Loza, et al.
Arthritis Research & Therapy|August 11, 2018
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trialTanja Alexandra Stamm, Klaus Peter Machold, Daniel Aletaha, et al.
Pageof 3